Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients

Retrovirology

Volumn 9, Issue , 2012, Pages

  Theys, Kristof ^a   Deforche, Koen ^b   Vercauteren, Jurgen ^a   Libin, Pieter ^b   van de Vijver, David A M C ^c,aa   Albert, Jan ^d   Åsjö, Birgitta ^e   Balotta, Claudia ^f   Bruckova, Marie ^g   Camacho, Ricardo J ^h,i   Clotet, Bonaventura ^j   Coughlan, Suzie ^k   Grossman, Zehava ^l   Hamouda, Osamah ^m   Horban, Andrzei ⁿ   Korn, Klaus ^o   Kostrikis, Leontios G ^p,aa   Kücherer, Claudia ^m   Nielsen, Claus ^q   Paraskevis, Dimitrios ^r   Poljak, Mario ^s   Puchhammer Stockl, Elisabeth ^t   Riva, Chiara ^f   Ruiz, Lidia ^j   Liitsola, Kirsi ^u   Schmit, Jean Claude ^v   Schuurman, Rob ^w   Sönnerborg, Anders ^x   Stanekova, Danica ^y   Stanojevic, Maja ^z   Struck, Daniel ^v   Van Laethem, K ^aa   Wensing, Annemarie M J ^w   Boucher, Charles A B ^c,w   Vandamme, A M ^aa   Puchhammer Stockl E , ^aa   Sarcletti, M ^aa   Schmied, B ^aa   Geit, M ^aa   Balluch, G ^aa   Vercauteren, J ^aa   Derdelinckx, I ^aa   Sasse, A ^aa   Bogaert, M ^aa   Ceunen, H ^aa   De Roo, A ^aa   De Wit, S ^aa   Deforche, K ^aa   Echahidi, F ^aa   Fransen, K ^aa   Goffard, J C ^aa   Goubau, P ^aa   Goudeseune, E ^aa   Yombi, J C ^aa   Lacor, P ^aa   Liesnard, C ^aa   Moutschen, M ^aa   Pierard, D ^aa   Rens, R ^aa   Schrooten, Y ^aa   Vaira, D ^aa   Van den Heuvel, A ^aa   Van Der Gucht, B ^aa   Van Ranst, M ^aa   Van Wijngaerden, E ^aa   Vandercam, B ^aa   Vekemans, M ^aa   Verhofstede, C ^aa   Clumeck, N ^aa   Demetriades, I ^aa   Kousiappa, I ^aa   Demetriou, V ^aa   Hezka, J ^aa   Linka, Marek ^aa   Bruckova, M ^aa   Machala, L ^aa   Nielsen, C ^aa   Jrgensen, L B ^aa   Gerstoft, J ^aa   Mathiesen, L ^aa   Pedersen, C ^aa   Nielsen, H ^aa   Laursen, A ^aa   Kvinesdal, B ^aa   Liitsola, K ^aa   Ristola, M ^aa   Suni, J ^aa   Sutinen, J ^aa   Korn, K ^aa   Kucherer C ^aa   Berg, T ^aa   Braun, P ^aa   Poggensee, G ^aa   Daumer M ^aa   Eberle, J ^aa   Heiken, H ^aa   Kaiser, R ^aa   Knechten, H ^aa   Muller H ^aa   Neifer, S ^aa   Schmidt, B ^aa   Walter, H ^aa   Gunsenheimer Bartmeyer, B ^aa   Harrer, T ^aa   Hatzakis, A ^aa   Paraskevis, D ^aa   Magiorkinis, E ^aa   Hatzitheodorou, E ^aa   Issaris, C ^aa   Haida, C ^aa   Zavitsanou, A ^aa   Magiorkinis, G ^aa   Lazanas, M ^aa   Chini, M ^aa   Magafas, N ^aa   Tsogas, N ^aa   Paparizos, V ^aa   Kourkounti, S ^aa   Antoniadou, A ^aa   Papadopoulos, A ^aa   Panagopoulos, P ^aa   Poulakou, G ^aa   Sakka, V ^aa   Chryssos, G ^aa   Drimis, S ^aa   Gargalianos, P ^aa   Lelekis, M ^aa   Xilomenos, G ^aa   Psichogiou, M ^aa   Daikos, G L ^aa   Panos, G ^aa   Haratsis, G ^aa   Kordossis, T ^aa   Kontos, A ^aa   Koratzanis, G ^aa   Theodoridou, M ^aa   Mostrou, G ^aa   Spoulou, V ^aa   Hall, W ^aa   De Gascun, C ^aa   Byrne, C ^aa   Duffy, M ^aa   Bergin, C ^aa   Reidy, D ^aa   Farrell, G ^aa   Lambert, J ^aa   O'Connor, E ^aa   Rochford, A ^aa   Low, J ^aa   Coakely, P ^aa   Coughlan, S ^aa   Grossman, Z ^aa   Levi, I ^aa   Chemtob, D ^aa   Balotta, C ^aa   Riva, C ^aa   Mussini, C ^aa   Caramma, I ^aa   Capetti, A ^aa   Colombo, M C ^aa   Rossi, C ^aa   Prati, F ^aa   Tramuto, F ^aa   Vitale, F ^aa   Ciccozzi, M ^aa   Angarano, G ^aa   Rezza, G ^aa   Schmit, J C ^aa   Struck, D ^aa   Hemmer, R ^aa   Arendt, V ^aa   Staub, T ^aa   Schneider, F ^aa   Roman, F ^aa   Wensing, A M J ^aa   Boucher, C A B ^aa   van Bentum, P H M ^aa   Brinkman, K ^aa   op de Coul, E L ^aa   van der Ende, M E ^aa   Hoepelman, I M ^aa   van Kasteren, M ^aa   Juttmann, J ^aa   Kuipers, M ^aa   Langebeek, N ^aa   Richter, C ^aa   Santegoets, R M W J ^aa   Schrijnders Gudde, L ^aa   Schuurman, R ^aa   van de Ven, B J M ^aa   Asjo B ^aa   Ormaasen, V ^aa   Aavitsland, P ^aa   Horban, A ^aa   Stanczak, J J ^aa   Stanczak, G P ^aa   Firlag Burkacka, E ^aa   Wiercinska Drapalo, A ^aa   Jablonowska, E ^aa   Malolepsza, E ^aa   Leszczyszyn Pynka, M ^aa   Szata, W ^aa   Camacho, R ^aa   Palma, C ^aa   Borges, F ^aa   Paixao T ^aa   Duque, V ^aa   Araujo F ^aa   Jevtovic, D J ^aa   Salemovic, D ^aa   Stanekova, D ^aa   Habekova, M ^aa   Mokras, M ^aa   Truska, P ^aa   Poljak, M ^aa   Babic, D ^aa   Tomazic, J ^aa   Vidmar, L ^aa   Karner, P ^aa   Clotet, B ^aa   Gutierrez C ^aa   deMendoza, C ^aa   Erkicia, I ^aa   Domingo, P ^aa   Camino, X ^aa   Galindo, M J ^aa   Blanco, J L ^aa   Leal, M ^aa   Masabeu, A ^aa   Guelar, A ^aa   Llibre, J M ^aa   Margall, N ^aa   Iribarren, J A ^aa   Gutierrez, S ^aa   Baldovi J F ^aa   Pedreira, J D ^aa   Gatell, J M ^aa   Moreno, S ^aa   de Mendoza, C ^aa   Soriano, V ^aa   Ruiz, L ^aa   Albert, J ^aa   Blaxhult, A ^aa   Heidarian, A ^aa   Karlsson, A ^aa   Aperia Peipke, K ^aa   Bergbrant, I M ^aa   Gisslen M ^aa   Svennerholm, M ^aa   Bjorkman P ^aa   Bratt, G ^aa   Carlsson, M ^aa   Ekvall, H ^aa   Ericsson, M ^aa   Hofer M ^aa   Johansson, B ^aa   Sonnerborg A ^aa   Kuylenstierna, N ^aa   Ljungberg, B ^aa   Makitalo S ^aa   Strand, A ^aa   Oberg S ^aa   more..

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Mybiodata Biomedical IT solutions   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITY OF MILAN   (Italy)

^g NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^h INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

ⁱ Centro Hospitalar de Lisboa Ocidental   (Portugal)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k UNIVERSITY COLLEGE DUBLIN   (Ireland)

^l TEL AVIV UNIVERSITY   (Israel)

^m ROBERT KOCH INSTITUTE   (Germany)

ⁿ SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^o UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^p UNIVERSITY OF CYPRUS   (Cyprus)

^q STATENS SERUM INSTITUT   (Denmark)

^r UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^s UNIVERSITY OF LJUBLJANA   (Slovenia)

^t MEDICAL UNIVERSITY OF VIENNA   (Austria)

^u NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^v LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^w UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^x KAROLINSKA INSTITUTE   (Sweden)

^y SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^z UNIVERSITY OF BELGRADE   (Serbia)

^aa NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866850986     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-9-81     Document Type: Article

References (47)

1. Vandamme AM, Van Laethem K, De Clercq E. Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Drugs 1999, 57:337-361. 10.2165/00003495-199957030-00006, 10193687.
2. Martinez-Picado J, Martinez MA. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res 2008, 134:104-123. 10.1016/j.virusres.2007.12.021, 18289713.
3. Verhofstede C, Wanzeele FV, Van Der Gucht B, De Cabooter N, Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999, 13:2541-2546. 10.1097/00002030-199912240-00007, 10630523.
4. Wensing AM, van de V, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de C, Ormaasen V, Paraskevis D, Perrin L, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005, 192:958-966. 10.1086/432916, 16107947.
5. Wensing A, Vercauteren J, van de V, Albert J, Åsjö B, Claudia B, Camacho R, Coughlan S, Grossman Z, Horban A, Kücherer C, Nielsen C, Paraskevis D, Loke W, Poggensee G, Riva C, Ruiz L, Schmit J, Schuurman R, Salminen M, Sonnerborg A, Stanojevic M, Struck D, Vandamme A, Boucher CA. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008, 22:625-635.
6. Vercauteren J, Wensing AM, van de V, Albert J, Balotta C, Hamouda O, Kücherer C, Struck D, Schmit JC, Asjö B, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Horban A, Korn K, Kostrikis L.G., Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Riva C, Ruiz L, Salminen M, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, Vandamme AM, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009, 200:1503-1508. 10.1086/644505, 19835478.
7. Simon V, Padte N, Murray D, Vanderhoeven J, Wrin T, Parkin N, Di Mascio M, Markowitz M. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection. J Virol 2003, 77:7736-7745. 10.1128/JVI.77.14.7736-7745.2003, 161921, 12829813.
8. Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, Jurriaans S, van der Hoek L. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther (Lond) 2006, 11:173-178.
9. van Maarseveen NM, de Jong D, Boucher CA, . Nijhuis M An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs. J Acquir Immune Defic Syndr 2006, 42:162-168. 10.1097/01.qai.0000219787.65915.56, 16645546, Nijhuis M.
10. Cong ME, Heneine W, García-Lerma JG. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007, 81:3037-3041. 10.1128/JVI.02712-06, 1865994, 17192300.
11. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181-188. 10.1001/jama.288.2.181, 12095382.
12. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, Gingeras TR. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996, 2:753-759. 10.1038/nm0796-753, 8673920.
13. Holguin A, Sune C, Hamy F, Soriano V, Klimkait T. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol 2006, 36:264-271. 10.1016/j.jcv.2006.05.001, 16765636.
14. Martinez-Picado J, Savara AV, Shi L, Sutton L, D'Aquila RT. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000, 275:318-322. 10.1006/viro.2000.0527, 10998332.
15. Alizon S, von Wyl V, Stadler T, Kouyos RD, Yerly S, Hirschel B, Boni J, Shah C, Klimkait T, Furrer H, Rauch A, Vernazza PL, Bernasconi E, Battegay M, Burgisser P, Telenti A, Gunthard HF, Bonhoeffer S. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog 2010, 6:e1001123. 10.1371/journal.ppat.1001123, 2947993, 20941398.
16. Tang J, Tang S, Lobashevsky E, Zulu I, Aldrovandi G, Allen S, Kaslow RA. HLA allele sharing and HIV type 1 viremia in seroconverting Zambians with known transmitting partners. AIDS Res Hum Retroviruses 2004, 20:19-25. 10.1089/088922204322749468, 15000695.
17. Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, Busch MP, Petropoulos CJ, Hellmann NS, Kahn JO, Grant RM. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 2004, 190:251-256. 10.1086/422036, 15216458.
18. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, Mandaliya K, Jaoko W, Overbaugh J. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007, 195:1177-1180. 10.1086/512682, 17357054.
19. Deforche K, Camacho R, Van Laethem K, Lemey P, Rambaut A, Moreau Y, Vandamme AM. Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment. Bioinformatics 2008, 24:34-41. 10.1093/bioinformatics/btm540, 18024973.
20. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de V, Rhee SY, Liu TF, Pillay D, Shafer RW. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance 2009, update. PLoS ONE 2009, 4:e4724. 10.1371/journal.pone.0004724, 2648874, 19266092.
21. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008, 10:67-84. 2547476, 18615118.
22. Peuchant O, Thiebaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, Morlat P, Dabis F, Fleury H, Masquelier B, Dabis F, Chene G, Dabis F, Lawson-Ayayi S, Thiebaut R, Winnock M, Bonarek M, Bonnal F, Bonnet F, Bernard N, Caubet O, Caunegre L, Cazanave C, Ceccaldi J, Couzigou P, Dauchy FA, De La Taille C, De Witte MC, Dupon M, Duffau P, Dutronc H, et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 2008, 22:1417-1423. 10.1097/QAD.0b013e3283034953, 18614864.
23. Bhaskaran K, Pillay D, Walker AS, Fisher M, Hawkins D, Gilson R, McLean K, Porter K. Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. AIDS 2004, 18:1471-1473. 10.1097/01.aids.0000131341.45795.33, 15199326.
24. Jakobsen MR, Tolstrup M, Søgaard OS, Jørgensen LB, Gorry PR, Laursen A, Ostergaard L. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis 2010, 50:566-573. 10.1086/650001, 20085464.
25. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, . Delaporte E Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000, 38:3919-3925. 87518, 11060045, Delaporte E.
26. Turner D, Roldan A, Brenner B, Moisi D, Routy JP, . Wainberg MA Variability in the PR and RT genes of HIV-1 isolated from recently infected subjects. Antivir Chem Chemother 2004, 15:255-259. Wainberg MA.
27. Campbell TB, Schneider K, Wrin T, Petropoulos CJ, Connick E. Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J Virol 2003, 77:12105-12112. 10.1128/JVI.77.22.12105-12112.2003, 253754, 14581547.
28. Daar ES, Kesler KL, Wrin T, Petropoulo CJ, Bates M, Lail A, Hellmann NS, Gomperts E, Donfield S. HIV-1 pol replication capacity predicts disease progression. AIDS 2005, 19:871-877. 10.1097/01.aids.0000171400.15619.e1, 15905667.
29. De Luca A, Weidler J, Di Giambenedetto S, Coakley E, Cingolani A, Bates M, Lie Y, Pesano R, Cauda R, Schapiro J. Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. J Acquir Immune Defic Syndr 2007, 45:411-417. 10.1097/QAI.0b013e318074f008, 17554216.
30. Goetz MB, Leduc R, Wyman N, Kostman JR, Labriola AM, Lie Y, Weidler J, Coakley E, Bates M, Luskin-Hawk R. HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr 2010, 53:472-479. 10.1097/QAI.0b013e3181cae480, 2837106, 20032783.
31. Santos AF, Abecasis AB, Vandamme AM, Camacho RJ, Soares MA. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. J Antimicrob Chemother 2009, 63(3):593-599. 10.1093/jac/dkn526, 19136678.
32. Santos AF, Tebit DM, Lalonde MS, Abecasis AB, Ratcliff A, Camacho RJ, Diaz RS, Herchenroder O, Soares MA, Arts EJ. Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility. Antimicrob Agents Chemother 2012, 56(5):2719-2725. 10.1128/AAC.06079-11, 3346603, 22330918.
33. Henderson GJ, Lee SK, Irlbeck DM, Harris J, Kline M, Pollom E, Parkin N, Swanstrom R. Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity. Antimicrob Agents Chemother 2012, 56(2):623-633. 10.1128/AAC.05549-11, 3264268, 22083488.
34. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Krausslich HG, Hance AJ, Clavel F. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog 2009, 5(3):e1000345. 10.1371/journal.ppat.1000345, 2652074, 19300491.
35. Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, Rosato PC, Kadie CM, Carlson JM, Markle TJ, Streeck H, Kelleher AD, Markowitz M, Jessen H, Rosenberg E, Altfeld M, Harrigan PR, Heckerman D, Walker BD, Allen TM. Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol 2010, 84(22):11937-11949. 10.1128/JVI.01086-10, 2977869, 20810731.
36. Lemey P, Rambaut A, Pybus OG. HIV evolutionary dynamics within and among hosts. AIDS Rev 2006, 8:125-140.
37. Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, Peres S, Carvalho AP, Mansinho K, Vandamme AM, Camacho R. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 2008, 5:12. 10.1186/1742-4690-5-12, 2265747, 18241328.
38. Paredes R, Clotet B. Clinical management of HIV-1 resistance. Antiviral Res 2010, 85:245-265. 10.1016/j.antiviral.2009.09.015, 19808056.
39. Theys K, Deforche K, Beheydt G, Moreau Y, van Laethem K, Lemey P, Camacho RJ, Rhee SY, Shafer RW, Van Wijngaerden E, Vandamme AM. Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape. BMC Bioinformatics 2010, 11:409. 10.1186/1471-2105-11-409, 2921410, 20682040.
40. Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, d' Arminio Monforte A. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001, 184:983-991. 10.1086/323604, 11574912.
41. Herbeck JT, Muller V, Maust BS, Ledergerber B, Torti C, Di Giambenedetto S, Gras L, Gunthard HF, Jacobson LP, Mullins JI, Gottlieb GS. Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. AIDS 2012, 26:193-205. 10.1097/QAD.0b013e32834db418, 22089381.
42. Deforche K, Silander T, Camacho R, Grossman Z, Soares MA, Van Laethem K, Kantor R, Moreau Y, Vandamme AM. Analysis of HIV-1 pol sequences using Bayesian networks: implications for drug resistance. Bioinformatics 2006, 22:2975-2979. 10.1093/bioinformatics/btl508, 17021157.
43. Theys K, Deforche K, Libin P, Camacho RJ, Van Laethem K, Vandamme AM. Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine. J Gen Virol 2010, 91:1898-1908. 10.1099/vir.0.022657-0, 20410311.
44. Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho RJ, Kjaer J, Van Laethem K, Phillips A, Moreau Y, Lundgren JD, Vandamme AM. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. Antivir Ther (Lond) 2008, 13:399-407.
45. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, Snoeck J, van Rensburg EJ, Wensing AM, van de V, Boucher CA, Camacho R, Vandamme AM. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005, 21:3797-3800. 10.1093/bioinformatics/bti607, 16076886.
46. Boutwell CL, Rolland MM, Herbeck JT, Mullins JI, Allen TM. Viral evolution and escape during acute HIV-1 infection. J Infect Dis 2010, 202(Suppl 2):S309-S314. 2945609, 20846038.
47. Langford S, Ananworanich J, Cooper D. Predictors of disease progression in HIV infection: a review. AIDS Res Ther 2007, 4:11. 10.1186/1742-6405-4-11, 1887539, 17502001.